Roche Holding Value Stock - Dividend - Research Selection
Roche
ISIN: CH0012032048 , WKN: 855167
Market price:
Fundamental data and company key figures of the share
| Annual reports in | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | |||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | |||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | |
| Market Capitalization | USD |
| Country | |
| Indices | |
| Sectors | |
| Raw Data Source | |
| Stock Split | |
| Internet |
Description of the company
At Roche, we believe in doing what should be done, rather than what has been done. So we follow where the science leads. We focus on today and look beyond tomorrow to tackle the world’s most formidable healthcare challenges.
Focus on medical need
Scientific breakthroughs are most likely to occur when scientists are free to tackle problems from different angles and in different ways. Our scientists have this freedom.
With radical scientific thinking and a deep understanding of disease mechanisms and therapies, we aim to produce the safest, most effective treatments available. Right now, we’re developing medicines in the areas where we see the greatest need:
In Oncology, our scientists are leaders in the identification of novel cell surface molecules and are working to characterise tumour antigens that may be useful in fighting various forms of cancer.
In Immunology, we’re constantly growing our expertise so that we can continue to discover and develop innovative medicines for patients living with debilitating diseases, such as rheumatoid arthritis or asthma.
Infectious diseases: Viral and bacterial infections are among the leading causes of disability and death. We’re committed to finding effective treatments for life-threatening infectious diseases.
In Neuroscience, we’re developing medicines for a range of serious brain diseases, including schizophrenia, Alzheimer’s disease, multiple sclerosis, depression, Parkinson’s disease, Down syndrome and autism.
Seeing the big picture
We make in vitro diagnostic tests for hospitals, commercial laboratories, physicians and patients. These can be used on blood, tissue or other patient samples to find and diagnose diseases and infections, select the right treatment and monitor how patients respond. Now, we’re able to test large numbers of samples in central labs faster, more reliably, and more efficiently than ever before. And more often than not, we can apply these new technologies at the earliest stages of targeted treatment development.
Collaboration is the key
Our greatest innovations grow from deep partnerships and collaboration with some of the smartest people and organisations in the industry. That’s how we’re building a better future for patients everywhere.